人 MGMT 抗体对
01AB00312
O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that directly reverses alkylation damage at the O-6 position of guanine, preventing mutagenic mismatches during replication. This monomeric protein (21.7 kDa) employs a suicide mechanism, transferring alkyl groups to its active site cysteine residue (Cys145), irreversibly inactivating itself. Expressed ubiquitously, particularly in the liver and brain, MGMT safeguards genomic integrity by mitigating G:C to A:T mutations. In cancer, epigenetic silencing via promoter methylation reduces MGMT expression, a hallmark of gliomas, glioblastomas, and other malignancies. Tumors with methylated MGMT promoters exhibit heightened sensitivity to alkylating agents like temozolomide, as impaired repair leads to lethal DNA damage accumulation. Conversely, unmethylated promoters correlate with therapeutic resistance, making MGMT status a critical biomarker for predicting chemotherapy efficacy.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- MGMT
- 蛋白别名
- O-6-methylguanine-DNA methyltransferase; MGMT
- UniProt
- P16455
- 物种
- Human
产品详情
- 靶点名称
- MGMT
- 蛋白名称
- O-6-methylguanine-DNA methyltransferase
- 蛋白别名
- Methylated-DNA--protein-cysteine methyltransferase; 6-O-methylguanine-DNA methyltransferase; MGMT; O-6-methylguanine-DNA-alkyltransferase
- 靶点基因名
- MGMT
- UniProt
- P16455
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that directly reverses alkylation damage at the O-6 position of guanine, preventing mutagenic mismatches during replication. This monomeric protein (21.7 kDa) employs a suicide mechanism, transferring alkyl groups to its active site cysteine residue (Cys145), irreversibly inactivating itself. Expressed ubiquitously, particularly in the liver and brain, MGMT safeguards genomic integrity by mitigating G:C to A:T mutations. In cancer, epigenetic silencing via promoter methylation reduces MGMT expression, a hallmark of gliomas, glioblastomas, and other malignancies. Tumors with methylated MGMT promoters exhibit heightened sensitivity to alkylating agents like temozolomide, as impaired repair leads to lethal DNA damage accumulation. Conversely, unmethylated promoters correlate with therapeutic resistance, making MGMT status a critical biomarker for predicting chemotherapy efficacy.